• Wondering if Albemarle's recent share price strength still leaves room for value, or if you are looking at a stock that has already run too far?
• Albemarle's stock last closed at US$194.82, with returns of 4.2% over 7 days, 9.4% over 30 days, 35.4% year to date and 244.8% over the last year.
• Recent headlines have focused on Albemarle's role in lithium and specialty chemicals markets, which often puts attention on how sensitive the stock can be to shifts in sentiment around these themes. For investors, that news flow helps explain why price moves can be sharp even without constant changes in the underlying fundamentals.
• Despite this performance, Albemarle currently has a valuation score of 0/6. The rest of this article will walk through standard valuation methods and then finish with a deeper way of thinking about what that score really means for you.

Albemarle scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Albemarle Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today using a required return, to estimate what the business might be worth right now.

For Albemarle, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is reported at about $152.2 million. Analysts provide explicit free cash flow estimates for several years ahead, including $971.1 million in 2026 and $1,050.3 million in 2027, with $479.4 million in 2028. Beyond that, Simply Wall St extrapolates cash flows through to 2035, all in dollar terms.

Discounting these projected cash flows back to today gives an estimated intrinsic value of about $34.95 per share. Compared with the recent share price of $194.82, the DCF output suggests Albemarle is trading at a significant premium, with an implied overvaluation of roughly 457.4%.

This model points to a wide gap between the cash flow based value and where the stock is trading today.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Albemarle may be overvalued by 457.4%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Albemarle Price vs Sales

For companies where profits can be volatile, the P/S ratio is often a useful cross check because it compares the stock price with the revenue that the business generates, rather than its current earnings.

What counts as a “normal” or “fair” P/S ratio usually reflects how investors see the company’s growth potential and risk. Higher expected growth and lower perceived risk often line up with a higher multiple, while slower growth or higher uncertainty tend to justify a lower figure.

Albemarle currently trades on a P/S ratio of 4.47x. That compares with a Chemicals industry average P/S of 1.15x and a peer average of 2.97x, so the stock is priced above both of those reference points. Simply Wall St’s Fair Ratio for Albemarle is 1.83x. This is a proprietary estimate of what the P/S might be given factors such as earnings growth, industry, profit margins, market cap and specific risks.

Because the Fair Ratio blends these company specific drivers instead of relying only on broad peer or industry comparisons, it can give a more tailored view of whether the current multiple looks stretched or conservative. In Albemarle’s case, the actual P/S of 4.47x sits well above the Fair Ratio of 1.83x, which points to the stock looking expensive on this metric.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Albemarle Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St’s Community page let you attach a clear story to your Albemarle numbers by linking your view of the business to a forecast and then to a Fair Value that you can compare directly with the current price.

In practice, a Narrative is your interpretation of the company. For example, one investor might argue that lithium demand, cost discipline and margin recovery can justify a Fair Value near US$245. Another might focus on technology risks, regulation and more modest growth that lines up closer to US$58. The platform shows both of these side by side so you can see how different assumptions feed into different Fair Values.

Because these Narratives update when new news, guidance or earnings are added to the system, you are not locked into a static view. This can help you decide whether Albemarle looks closer to a buy, a hold or a sell for your own approach whenever the gap between Fair Value and price changes.

For Albemarle however we will make it really easy for you with previews of two leading Albemarle Narratives:

Fair value: US$245.00

Implied discount to this narrative: 20.5% below its fair value

Revenue growth assumption: 16.1%

• Counts on lithium pricing support, cost discipline and higher production to lift margins and free cash flow.
• Builds on expectations for strong electrification trends and tighter lithium supply to support pricing power.
• Uses a Fair Value of US$245 based on higher revenue, much higher profit margins and a lower P/E than the current US Chemicals industry multiple.

Fair value: US$172.62

Implied premium to this narrative: 12.9% above its fair value

Revenue growth assumption: 7.9%

• Assumes lithium demand and contracts support revenue, but also highlights risks from oversupply and pricing pressure.
• Emphasizes cost reductions, productivity efforts and long term contracts to support cash flow and margins.
• Uses a Fair Value of about US$172.62 that reflects more moderate revenue growth, mid teens profit margins and an 11.9x P/E on expected 2028 earnings.

These two Narratives present a wide but clearly defined range of fair values. Your task is to decide which set of assumptions feels closer to how you see Albemarle's future and adjust from there.

Do you think there's more to the story for Albemarle? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.